In Reply As noted in my article,1 the development of antisense drugs has not been easy. Matsui and I have recently described at length2 some of these difficulties and the lessons they offer for contemporary science. Unfortunately, Bhagavati’s letter, while correctly appreciating that results should be treated skeptically, falls short in other respects.
Corey DR. Doubts About Therapy for Neurological Diseases With Antisense Oligonucleotides—Reply. JAMA Neurol. 2016;73(12):1502–1503. doi:10.1001/jamaneurol.2016.4335
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: